Paratek Pharmaceuticals (NASDAQ:PRTK) and Ekso Bionics (NASDAQ:EKSO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.
Earnings and Valuation
This table compares Paratek Pharmaceuticals and Ekso Bionics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Paratek Pharmaceuticals | $16.54 million | 13.43 | $-128,790,000.00 | ($3.93) | -1.31 |
| Ekso Bionics | $13.92 million | 4.01 | $-12,130,000.00 | ($3.45) | -2.13 |
Ekso Bionics has lower revenue, but higher earnings than Paratek Pharmaceuticals. Ekso Bionics is trading at a lower price-to-earnings ratio than Paratek Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Paratek Pharmaceuticals has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500.
Profitability
This table compares Paratek Pharmaceuticals and Ekso Bionics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Paratek Pharmaceuticals | -528.28% | N/A | -47.65% |
| Ekso Bionics | -68.97% | -210.43% | -59.23% |
Insider and Institutional Ownership
43.4% of Paratek Pharmaceuticals shares are held by institutional investors. Comparatively, 23.5% of Ekso Bionics shares are held by institutional investors. 7.7% of Paratek Pharmaceuticals shares are held by company insiders. Comparatively, 24.3% of Ekso Bionics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Paratek Pharmaceuticals and Ekso Bionics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Paratek Pharmaceuticals | 0 | 0 | 6 | 0 | 3.00 |
| Ekso Bionics | 0 | 0 | 3 | 0 | 3.00 |
Paratek Pharmaceuticals presently has a consensus price target of $18.50, suggesting a potential upside of 259.22%. Ekso Bionics has a consensus price target of $11.00, suggesting a potential upside of 49.66%. Given Paratek Pharmaceuticals' higher probable upside, research analysts plainly believe Paratek Pharmaceuticals is more favorable than Ekso Bionics.
Summary
Paratek Pharmaceuticals beats Ekso Bionics on 8 of the 13 factors compared between the two stocks.
